Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.64 |
| ▸ | RAB9A | P51151 | 2/20 | 0.64 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.64 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.58 |
| ▸ | CA12 | O43570 | 1/20 | 0.58 |
| ▸ | CA1 | P00915 | 1/20 | 0.58 |
| ▸ | CA2 | P00918 | 1/20 | 0.58 |
| ▸ | CA7 | P43166 | 1/20 | 0.58 |
| ▸ | CA9 | Q16790 | 1/20 | 0.58 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.58 |
| ▸ | MAOB | P27338 | 2/20 | 0.53 |
| ▸ | MAOA | P21397 | 1/20 | 0.53 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | CASP3 | P42574 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.52 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.52 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7024215 | 0.92 | — | — | |
| SCHEMBL8298 | 0.92 | — | — | |
| SCHEMBL19660767 | 0.87 | MAPT (0.68) | NPC1RAB9ANFE2L2ESR2MAOB | |
| SCHEMBL18390947 | 0.87 | NPC1 (0.53) | NPC1RAB9ANFE2L2ESR2CA12 | |
| SCHEMBL197522 | 0.86 | CA1 (0.79) | NPC1RAB9AESR2CA12CA1 | |
| SCHEMBL6733562 | 0.86 | CA1 (0.79) | NPC1RAB9AESR2CA12CA1 | |
| SCHEMBL9151672 | 0.86 | CA1 (0.79) | NPC1RAB9AESR2CA12CA1 | |
| SCHEMBL5175480 | 0.84 | NFE2L2 (0.64) | NPC1RAB9ANFE2L2CA12CA1 | |
| SCHEMBL10800839 | 0.84 | ABL1 (0.50) | NPC1RAB9ANFE2L2TP53MAPK1 | |
| SCHEMBL2833469 | 0.83 | NPC1 (0.57) | NPC1RAB9ANFE2L2ESR2CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240246940-A1 | HETEROARYL DERIVATIVE COMPOUND AND USE THEREOF | VORONOI INC. (KR) | 2024-07-25 | — | — | US | claimed |
| US-7723348-B2 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORPORATION (US) | 2010-05-25 | — | — | US | claimed |
| US-7432266-B2 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORPORATION (US) | 2008-10-07 | — | — | US | claimed |
| US-20080207660-A1 | PHOSPHODIESTERASE 4 INHIBITORS | HOPPER ALLEN | 2008-08-28 | — | — | US | claimed |
| US-20060154960-A1 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORPORATION | 2006-07-13 | — | — | US | claimed |
| CN-118834121-A | Method for preparing biaryl compound by cross-coupling of diazonium salt and aryl bromide under nickel catalysis | 浙江工业大学 | 2024-10-25 | — | — | CN | disclosed |
| CN-117986097-B | Novel method for Suzuki coupling based on photocatalysis | 科莱博(江苏)科技股份有限公司 | 2024-07-19 | — | — | CN | disclosed |
| CN-118324596-A | Synthesis method of biaryl compound | 新疆大学 | 2024-07-12 | — | — | CN | disclosed |
| US-20240218002-A1 | PHOSPHINE-UREA LIGANDS FOR TRANSITION METAL CATALYZED CROSS-COUPLING REACTIONS | THE TEXAS A&M UNIVERSITY SYSTEM (US) | 2024-07-04 | — | — | US | disclosed |
| US-20240149262-A1 | Immobilization of Molecular Catalysts on Solid Powders via Vapor Deposition of Encapsulating Nano-Layers for Use as Heterogeneous Chemical Catalysts | UNIVERSITY OF SOUTH CAROLINA | 2024-05-09 | — | — | US | disclosed |
| CN-117986097-A | Novel method for Suzuki coupling based on photocatalysis | 科莱博(江苏)科技股份有限公司 | 2024-05-07 | — | — | CN | disclosed |
| US-11697695-B2 | Polymerizable composition and optically anisotropic body using same | DIC CORPORATION (JP) | 2023-07-11 | — | — | US | disclosed |
| US-20060154960-A1 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORPORATION | 2006-07-13 | — | — | US | disclosed |
| US-20040254066-A1 | Dissolving or dispersion forming emulsion; transition metal catalyst encapsulated within a permeable polymer; catalyst for foirming polyol from olefin | REAXA LIMITED (GB) | 2004-12-16 | — | — | US | disclosed |
| EP-1409125-A1 | MICROENCAPSULATED CATALYST, METHODS OF PREPARATION AND METHODS OF USE THEREOF | Avecia Limited (GB) | 2004-04-21 | — | — | EP | disclosed |
| EP-1334094-A1 | CHOLESTEROL LOWERING BENZO[B]THIOPHENES AND BENZO[D]ISOTHIAZOLES | F. HOFFMANN-LA ROCHE AG (CH) | 2003-08-13 | — | — | EP | disclosed |
| WO-2003006151-A1 | MICROENCAPSULATED CATALYST, METHODS OF PREPARATION AND METHODS OF USE THEREOF | AVECIA LIMITED (GB) | 2003-01-23 | — | — | WO | disclosed |
| WO-2002036584-A1 | CHOLESTEROL LOWERING BENZO`B! THIOPHENES AND BENZO`D! ISOTHIAZOLES | F. HOFFMANN-LA ROCHE AG (CH) | 2002-05-10 | — | — | WO | disclosed |
| US-6242654-B1 | REACTING A PHENOLATE COMPOUND WITH AN ORGANIC FLUORINATING AGENT TO PREPARE A FLUORINE SUBSTITUTED AROMATIC COMPOUND | MITSUI CHEMICALS, INC. (JP) | 2001-06-05 | — | — | US | disclosed |
| EP-1013629-A1 | Preparation process of fluorine subsituted aromatic compound | Mitsui Chemicals, Inc. (JP) | 2000-06-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240246940-A1 | HETEROARYL DERIVATIVE COMPOUND AND USE THEREOF | ERBB2, EGFR, ERBB3 | NPC1 1484/4885RAB9A 1378/4885NFE2L2 224/4885 |
| US-20080207660-A1 | PHOSPHODIESTERASE 4 INHIBITORS | PDE4A, PDE4B, PDE12 | NPC1 4728/4885RAB9A 1437/4885NFE2L2 4193/4885 |
| US-20060154960-A1 | Phosphodiesterase 4 inhibitors | PDE4A, PDE4B, PDE12 | NPC1 4728/4885RAB9A 1437/4885NFE2L2 4193/4885 |
| US-20240218002-A1 | PHOSPHINE-UREA LIGANDS FOR TRANSITION METAL CATALYZED CROSS-COUPLING REACTIONS | NUDC, NPM1, PNP | NPC1 3078/4885RAB9A 1277/4885NFE2L2 2192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.